191 related articles for article (PubMed ID: 20857142)
1. TLE1 expression in malignant mesothelioma.
Matsuyama A; Hisaoka M; Iwasaki M; Iwashita M; Hisanaga S; Hashimoto H
Virchows Arch; 2010 Nov; 457(5):577-83. PubMed ID: 20857142
[TBL] [Abstract][Full Text] [Related]
2. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
[TBL] [Abstract][Full Text] [Related]
3. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
4. Pleural malignant mesothelioma versus pleuropulmonary synovial sarcoma: a clinicopathological study of 22 cases with molecular analysis and survival data.
Klebe S; Prabhakaran S; Hocking A; Pulford E; Moore S; Nicola M; Allen PW; Henderson DW
Pathology; 2018 Oct; 50(6):629-634. PubMed ID: 30170702
[TBL] [Abstract][Full Text] [Related]
5. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms.
Attanoos RL; Dojcinov SD; Webb R; Gibbs AR
Histopathology; 2000 Sep; 37(3):224-31. PubMed ID: 10971698
[TBL] [Abstract][Full Text] [Related]
6. Expression of mesothelial markers in malignant mesotheliomas: an immunohistochemical evaluation of 173 cases.
Soomro IN; Oliveira R; Ronan J; Chaudry ZR; Johnson J
J Pak Med Assoc; 2005 May; 55(5):205-9. PubMed ID: 15960287
[TBL] [Abstract][Full Text] [Related]
7. Transducer-like enhancer of split 1 (TLE1) expression as a diagnostic immunohistochemical marker for synovial sarcoma and its association with morphological features.
Bakrin IH; Hussain FA; Tuan Sharif SE
Malays J Pathol; 2016 Aug; 38(2):117-22. PubMed ID: 27568668
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical validation of TLE1, a novel marker, for synovial sarcomas.
Rekhi B; Basak R; Desai SB; Jambhekar NA
Indian J Med Res; 2012 Nov; 136(5):766-75. PubMed ID: 23287123
[TBL] [Abstract][Full Text] [Related]
9. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms.
Kosemehmetoglu K; Vrana JA; Folpe AL
Mod Pathol; 2009 Jul; 22(7):872-8. PubMed ID: 19363472
[TBL] [Abstract][Full Text] [Related]
10. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
11. TLE1 is expressed in the majority of primary pleuropulmonary synovial sarcomas.
Lino-Silva LS; Flores-Gutiérrez JP; Vilches-Cisneros N; Domínguez-Malagón HR
Virchows Arch; 2011 Dec; 459(6):615-21. PubMed ID: 22071579
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
Ordóñez NG
Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
[TBL] [Abstract][Full Text] [Related]
13. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma.
Jagdis A; Rubin BP; Tubbs RR; Pacheco M; Nielsen TO
Am J Surg Pathol; 2009 Dec; 33(12):1743-51. PubMed ID: 19809272
[TBL] [Abstract][Full Text] [Related]
15. Tissue microarray based immunohistochemical study of TLE1 in synovial sarcoma and its histologic mimics.
Sivakoti S; Uppin SG; Uppin MS; Tara RP; Prayaga AK; Challa S
Indian J Pathol Microbiol; 2021; 64(2):310-315. PubMed ID: 33851625
[TBL] [Abstract][Full Text] [Related]
16. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
17. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
Berg KB; Churg A
Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203
[TBL] [Abstract][Full Text] [Related]
18. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
19. Specificity of TLE1 expression in unclassified high-grade sarcomas for the diagnosis of synovial sarcoma.
Valente AL; Tull J; Zhang S
Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):408-13. PubMed ID: 23197007
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic study of deciduoid mesothelioma using SMARCB1/INI1 immunohistochemistry and fluorescence in situ hybridization.
Kawai T; Ogata S; Nakashima H; Urabe S; Murakami I; Hiroshima K
Hum Pathol; 2019 Nov; 93():23-29. PubMed ID: 31445842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
